Floatz logo

HYROGEN PEROXIDE

Basal Cell Carcinoma

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Basal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Genentech, Inc.
Phase 2BB
Eloxatin
Genzada Pharmaceuticals USA, Inc.
Phase 2BB
FLUOROURACILUM
Genentech, Inc.
Phase 2B
Gdc-0449
Genentech, Inc.
Phase 2B
Calcium folinate pentahydrate
Genentech, Inc.
Phase 2B

View all 31 →

Same molecule, other indications

HYROGEN PEROXIDE is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Squamous Cell Carcinoma of Skin DifferentiatedDormant
CCC
Indicative ·
53 / 100
View asset →
multiple sclerosisDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →